- Details
- Oliver Sartor speaks with Emanuele Ostuni about ARTBIO’s focus on radiopharmaceuticals, particularly lead-212. Dr. Ostuni explains ARTBIO’s choice of lead-212 for its short half-life, which better matches the biological half-lives of targeting ligands. He discusses the manufacturing and distribution challenges associated with short-lived isotopes and outlines ARTBIO’s approach to developing a netw...
|
- Details
- Andrea Miyahira discusses with Irene Casanova-Salas and Joaquin Mateo a Cancer Cell publication on using circulating tumor extracellular vesicles (EVs) to monitor metastatic prostate cancer evolution. The researchers describe their novel method for analyzing both DNA and RNA from EVs in patient plasma samples. They highlight the advantages of EV analysis over traditional ctDNA, including the abili...
|
- Details
- Rashid Sayyid and Zach Klaassen review the 2024 NCCN prostate cancer guideline updates focusing on treatment-related bone loss in patients on androgen deprivation therapy (ADT). They emphasize the importance of addressing bone health due to increased fracture risk associated with ADT. The speakers outline a comprehensive approach to bone health management, including risk assessment using the FRAX...
|
- Details
- Rashid Sayyid and Zach Klaassen review the NCCN prostate cancer guideline updates regarding the prevention of symptomatic skeletal-related events in bone metastatic CRPC patients. They discuss the efficacy and safety profiles of denosumab and zoledronic acid, highlighting key clinical trials that have shaped current recommendations. The speakers emphasize the importance of considering dosing frequ...
|
- Details
- Andrea Miyahira interviews Michael Haffner about his group's study on the expression of TROP2, CEACAM5, and DLL3 in metastatic prostate cancer, published in NEJM Evidence. Dr. Haffner discusses their analysis of over 750 samples from 52 patients in a rapid autopsy cohort, examining protein expression across different molecular subtypes of castration-resistant prostate cancer. The study reveals dis...
|
- Details
- Alicia Morgans interviews Karim Fizazi about the updated survival and quality of life data from the PSMAfore trial. The study compares lutetium PSMA to second-line AR pathway inhibitors in metastatic castration-resistant prostate cancer patients who have progressed after one AR pathway inhibitor. Dr. Fizazi discusses the trial's findings, highlighting a significant improvement in radiographic prog...
|
- Details
- Ruchika Talwar hosts Daniel Triner to discuss a study on the management of lymph node-positive prostate cancer after radical prostatectomy. Using data from the Michigan Urological Surgery Improvement Collaborative (MUSIC), Dr. Triner's team analyzes treatment patterns for 666 patients. They find that approximately two-thirds of patients receive secondary treatment within 12 months, with variations...
|
- Details
- Alicia Morgans interviews Omar El-Taji and Ashwin Sachdeva about their JAMA Oncology publication on cardiovascular risks associated with androgen receptor signaling inhibitors (ARSIs) in prostate cancer treatment. Their meta-analysis reveals that ARSIs significantly increase the risk of cardiovascular events across all stages of prostate cancer, with abiraterone and enzalutamide showing the highes...
|
- Details
- Zach Klaassen interviews Karen Hoffman about the PROSTATE-IQ trial, which aims to reduce the burden of androgen deprivation therapy (ADT) in men receiving salvage radiotherapy for prostate cancer. The trial incorporates the ArteraAI Prostate Test to stratify patients and explores alternative treatment strategies, including the use of apalutamide. Dr. Hoffman explains that the study focuses on impr...
|
- Details
- Bruce Montgomery discusses the pivotal role of germline testing in cancer predisposition, particularly within the Million Veterans Program. Focusing on prostate cancer, Dr. Montgomery explains that germline testing, which examines inherited DNA, can identify individuals with genetic predispositions to various cancers, including prostate, breast, ovarian, and pancreatic. This testing is crucial for...
|
